Oki, Yasuhiro <br/><br/>
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.  [electronic resource] 

 -  European journal of haematology  Dec 2008 
 - 448-53 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1600-0609 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0609.2008.01129.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lymphocyte Count<br/>Lymphoma, Large B-Cell, Diffuse--blood<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prednisone--administration & dosage<br/>Regression Analysis<br/>Retrospective Studies<br/>Risk Factors<br/>Rituximab<br/>Survival Rate<br/>Vincristine--administration & dosage